Jun 17, 2024
Mitsubishi Tanabe Pharma America Celebrates Second Anniversary of RADICAVA ORS® (edaravone) Launch in the U.S.
Feb 08, 2021
Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S.
Jan 14, 2021
Mitsubishi Tanabe Pharma America Announces Enhancements to Out-Of-Pocket Assistance Program for Eligible ALS Patients Treated with RADICAVA® (edaravone)
Dec 14, 2020
Mitsubishi Tanabe Pharma America Announces Initiation of Postmarketing Commitment Study Assessing Daily Dosing of Oral Edaravone in Patients with ALS
Dec 11, 2020
Mitsubishi Tanabe Pharma America Presents Real-World Experience Outcomes During IV Edaravone Treatment at Virtual 31st International Symposium on ALS/MND
Dec 03, 2020
Mitsubishi Tanabe Pharma America Announces Presentations of ALS Data at Virtual 31st International Symposium on ALS/MND
Nov 09, 2020
Mitsubishi Tanabe Pharma America Announces the Global Phase 3 Study of Oral Edaravone for ALS has Completed Enrollment
Sep 30, 2020
Mitsubishi Tanabe Pharma America Announces Presentations At Northeast Amyotrophic Lateral Sclerosis 19th Annual Meeting
Aug 24, 2020
Mitsubishi Tanabe Pharma America Announces Enrollment Has Resumed For The Global Phase 3 Study Of Oral Edaravone For ALS
May 20, 2020
Mitsubishi Tanabe Pharma America Announces Launch Of The JourneyMate Program, Offering Live Nurse Educational Phone Support For ALS Patients And Caregivers
May 05, 2020
Mitsubishi Tanabe Pharma America Marks Third Anniversary Of FDA Approval And Reports More Than 5,000 Patients With ALS Treated With RADICAVA® (edaravone)
Dec 04, 2019
Mitsubishi Tanabe Pharma America to Present Real-World Data on RADICAVA® (edaravone) for ALS at the 30th International Symposium on ALS/MND
Nov 25, 2019
Mitsubishi Tanabe Pharma America Announces Initiation of Phase 3 Study Evaluating Investigational Oral Formulation of Edaravone for ALS
Nov 05, 2019
Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (Edaravone) for Amyotrophic Lateral Sclerosis
Sep 26, 2019
Mitsubishi Tanabe Pharma America Announces Appointment Of Gustavo A. Suarez Zambrano, M.D., As Vice President, Medical Affairs
Sep 23, 2019
Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient-Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson's Disease and Movement Disorders
Sep 20, 2019
Mitsubishi Tanabe Pharma America To Present On ALS Clinical Programs At 2019 Muscle Study Group Annual Scientific Meeting
Aug 28, 2019
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
Aug 08, 2019
More Than 4,000 U.S. Patients With ALS Treated With RADICAVA® (edaravone) In Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports
May 06, 2019
MTPA Announces Nationwide Database Of ALS Infusion Services To Help Patients And Caregivers Identify Local Providers